Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity

Toxicology Letters

Volumn 205, Issue 1, 2011, Pages 47-54

  Xue, Xiang ^a   Gong, Likun ^a   Qi, Xinming ^a   Wu, Yuanfeng ^a   Xing, Guozhen ^a   Yao, Jun ^a   Luan, Yang ^a   Xiao, Ying ^a   Li, Yan ^a   Wu, Xiongfei ^a   Chen, Min ^a   Gu, Jun ^b   Ren, Jin ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Cytochrome P450; Toxicity; Triptolide; Xenobiotic metabolism

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CYTOCHROME P450 REDUCTASE; GLUCOSE; PROTEIN; TRIACYLGLYCEROL; TRIPTOLIDE; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOAVAILABILITY; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEATH; DETOXIFICATION; DUODENUM; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; GENE SILENCING; GLUCOSE BLOOD LEVEL; HEART; HISTOPATHOLOGY; HYDROXYLATION; KIDNEY; LEUKOCYTE COUNT; LIQUID CHROMATOGRAPHY; LIVER; LYMPHOCYTE COUNT; MALE; MASS SPECTROMETRY; METABOLITE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN; THROMBOCYTE COUNT; THYMUS; TISSUE LEVEL; TOXICOKINETICS; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; WILD TYPE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOXY COMPOUNDS; HYDROXYLATION; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER FUNCTION TESTS; MICE; MICE, KNOCKOUT; NADPH-FERRIHEMOPROTEIN REDUCTASE; PHARMACOKINETICS; PHENANTHRENES; PLATELET COUNT; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION;

ANIMALIA; MUS; RATTUS; TRIPTERYGIUM WILFORDII;

EID: 79960027848     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.05.003     Document Type: Article

References (23)

1. Ding W., Wu G.J., Chen J.Q., et al. Toxicological study of triptolide. Chin. Ophthal. Res. 1999, 17:343-345.
2. Dresser G.K., Spence J.D., Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 2000, 38:41-57.
3. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
4. Gu J., Weng Y., Zhang Q.Y., Cui H., Behr M., Wu L., Yang W., Zhang L., Ding X. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J. Biol. Chem. 2003, 278:25895-25901.
5. Gu J., Cui H., Behr M., Zhang L., Zhang Q.Y., Yang W., Hinson J.A., Ding X. In vivo mechanisms of tissue-selective drug toxicity: effects of liver-specific knockout of the NADPH-cytochrome P450 reductase gene on acetaminophen toxicity in kidney, lung, and nasal mucosa. Mol. Pharmacol. 2005, 67:623-630.
6. Guengerich F.P. Role of cytochrome P450 enzymes in drug-drug interactions. Adv. Pharmacol. 1997, 7-35.
7. Henderson C.J., Otto D.M., Carrie D., Magnuson M.A., McLaren A.W., Rosewell I., Wolf C.R. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J. Biol. Chem. 2003, 278:13480-13486.
8. Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 2002, 181-182:447-452.
9. Kuypers D.R., de Jonge H., Naesens M., Lerut E., Verbeke K., Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin. Pharmacol. Ther. 2007, 82:711-725.
10. Li W., Liu Y., He Y.Q., Zhang J.W., Gao Y., Ge G.B., Liu H.X., Huo H., Liu H.T., Wang L.M., Sun J., Wang Q., Yang L. Characterization of triptolide hydroxylation by cytochrome P450 in human and rat liver microsomes. Xenobiotica 2008, 38:1551-1565.
11. Lin N., Liu C., Xiao C., Jia H., Imada K., Wu H., Ito A. Triptolide, a diterpenoid triepoxide, suppresses inflammation and cartilage destruction in collagen-induced arthritis mice. Biochem. Pharmacol. 2007, 73:136-146.
12. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Walker J.R., Antman E.M., Macias W., Braunwald E., Sabatine M.S. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 2009, 360:354-362.
13. Ni B., Jiang Z., Huang X., Xu F., Zhang R., Zhang Z., Tian Y., Wang T., Zhu T., Liu J., Zhang L. Male reproductive toxicity and toxicokinetics of triptolide in rats. Arzneimittelforschung 2008, 58:673-680.
14. Pyatt D.W., Yang Y., Mehos B., Le A., Stillman W., Irons R.D. Hematotoxicity of the Chinese herbal medicine Tripterygium wilfordii hook f in CD34-positive human bone marrow cells. Mol. Pharmacol. 2000, 57:512-518.
15. Qiu D., Kao P.N. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D 2003, 4:1-18.
16. Seliskar M., Rozman D. Mammalian cytochromes P450--importance of tissue specificity. Biochim. Biophys. Acta 2007, 1770:458-466.
17. Shamon L.A., Pezzuto J.M., Graves J.M., Mehta R.R., Wangcharoentrakul S., Sangsuwan R., Chaichana S., Tuchinda P., Cleason P., Reutrakul V. Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii. Cancer Lett. 1997, 112:113-117.
18. Srivastava A., Maggs J.L., Antoine D.J., Williams D.P., Smith D.A., Park B.K. Role of reactive metabolites in drug-induced hepatotoxicity. Handb. Exp. Pharmacol. 2010, 196:165-194.
19. Tao X.L., Sun Y., Dong Y., Xiao Y.L., Hu D.W., Shi Y.P., Zhu Q.L., Dai H., Zhang N.Z. A prospective, controlled, double-blind, cross-over study of tripterygium wilfodii hook F in treatment of rheumatoid arthritis. Chin. Med. J. (Engl.) 1989, 102:327-332.
20. Xiao Y., Ge M., Xue X., Wang C., Wang H., Wu X., Li L., Liu L., Qi X., Zhang Y., Li Y., Luo H., Xie T., Gu J., Ren J. Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int. 2008, 73:1231-1239.
21. Ye X., Li W., Yan Y., Mao C., Cai R., Xu H., Yang X. Effects of cytochrome P4503A inducer dexamethasone on the metabolism and toxicity of triptolide in rat. Toxicol. Lett. 2010, 192:212-220.
22. Zhang Z., Zheng Q., Han J., Gao G., Liu J., Gong T., Gu Z., Huang Y., Sun X., He Q. The targeting of 14-succinate triptolide-lysozyme conjugate to proximal renal tubular epithelial cells. Biomaterials 2009, 30:1372-1381.
23. Zhou R., Zhang F., He P.L., Zhou W.L., Wu Q.L., Xu J.Y., Zhou Y., Tang W., Li X.Y., Yang Y.F., Li Y.C., Zuo J.P. (5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide analog mediates immunosuppressive effects in vitro and in vivo. Int. Immunopharmacol. 2005, 5:1895-1903.